Article

Alimera dry eye emollient drop hits market

Alimera Sciences Inc. introduces its lubricant eye drops, Soothe Emollient, the first multi-dose, emollient-based artificial tear product for dry-eye sufferers.

Alimera Sciences Inc. introduces its lubricant eye drops, Soothe Emollient, the first multi-dose, emollient-based artificial tear product for dry-eye sufferers. The product is slated to reach U.S. retail stores by Sept. 15.

Using Restoryl, an advanced lipid restorative, Soothe re-establishes the eye's protective lipid layer to reduce tear evaporation and seal essential moisture, giving patients up to 8 hours of comfort.

Alimera Sciences licensed the artificial tear product in November 2003 from Ocular Research of Boston (ORB), a group of eye-care specialists who focus on dry eye research. The agreement combined the medical expertise of ORB with the ophthalmic commercial experience of Alimera Sciences.

"This product was inspired by and developed for dry eye patients," said Donald Korb, MD, ORB president, in a company statement. "Because Soothe restores the compromised lipid layer of patients' tears, regardless of the particular dry eye state, harmful evaporation is minimized and the ocular surface is protected.

"Thus, doctors can be confident that they are giving their patients long-lasting relief," Dr. Korb said. "After years of perfecting the formula and finding the right partner, I am excited that Soothe will be accessible to patients in such a short time."

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.